1. Cosman F, de Beur SJ, LeBoff MS, et al. Clinicians guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25: 2359–2381.
2. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther 2004; 26: 841–854.
3. Solomon DH, Patric AR, Schousboe L, et al. The potential economic benefits of improved postfracture care: a cost–effectiveness analysis of a fracture liaison service in the US health-care systém. J Bone Miner Res 2014; 29: 1667–1674.
4. Kanis JA, Svedbom A, Harvey N, et al. The osteoporosis treatment gap. J Bone Miner Res 2014; 29: 1926–1928.
5. Quaseem A, Forciea MA, Mc Lean, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017; 166: 818–839.
6. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res 2015; 30: 3–23.
7. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29: 1–23.
8. Shane E, Burr D, Ebeling PR, et al. Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267–2294.
9. McClung MR, Harris ST, Miller PD, et al. Bisphosphonate therapy of osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126(1): 13–20.
10. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2016; 374(3): 254–262.
11. Mignot MA, Taisne N, Legroux I, et al. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int 2017; 28(12): 3431–3438.
12. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–789.
13. Meier RP, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172: 930–936.
14. Serrano AJ, Begona L, Anitua E, et al. Systematic review and metaanalysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol 2013; 29(12): 1005–1014.
15. Lee SH, Chang SS, Lee M, et al. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis. Osteoporos Int 2014; 23(3): 1131–1139.
16. Rogers MJ, Frith JC, Luckman SP, et al. Molecular mechanism of acrion of bisphosphonates. Bone 1999; 24: 73S–79S.
17. Fleisch H. Bisphosphonates: Mechanism of action. Endocr Rev 1998; 19: 80–100.
18. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effect on osteoklast ultrastructure. J Clin Invest 1991; 88: 2095–2105.
19. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478–1487.
20. Baron R, Ferrari S, Russell RG. Denosumab and Bisphosphonates: Different mechanism of action and effects. Bone 2011; 48: 677–692.
21. Russell RG, Watts NB, Ebetino FH, et al. Mechanism of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733–759.
22. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermitent therapy for osteoporosis. Clin Pharmacokinet 2005; 44: 551–570.
23. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoorosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 875–883.
24. Neele SJ, Evertz R, De Valk-De Roo, et al. Effect of 1 year od discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002; 30: 599–603.
25. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011; 22: 2951–2961.
26. Allen MR. Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact 2007; 7: 358–360.
27. Lesclous P, Abi Najm S, Carrel JP, et al. Bisphosphonate–assciated osteonecrosis of the jaw: A key role of inflammation? Bone 2009; 45: 843–852.
28. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24: 561–574.
29. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 2893–2897.
30. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567–1575.
31. Sim Ie, Sanders KM, Borromeo Gl, et al. Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer. J Clin Endocrinol Metab 2015; 100: 3887–3893.
32. Ng AC, Png MA, Mohan PC, et al. Atypical femoral fractures: Transverse morphology at lateral cortex is a critical feature. J Bone Miner Res 2014; 29: 639–643.
33. Koh JS, Goh SK, Png MA, et al. Distribution of atypical fractures and cortical stress lesions in the femur: Implications on pathophysiology. Singapore Med J 2011; 52: 77–80.
34. Nieves LW, Bilezikian JP, Lane JM, et al. Fragility fractures of the hip and femur: Incidence and patient characteristics. Osteoporos Int 2010; 21: 399–408.
35. Probyn L, Cheung AM, Lang C, et al. Bilateral atypical femoral fractures: How much symmetry is there on imaging? Skeletal Radiol 2015; 44: 1579–1584.
36. Giusti A, Hamdy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011; 48: 966–971.
37. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010; 47: 169–180.
38. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728–1737.
39. Gasser J, Ingold P, Rebmann A, et al. Inhibition of FPP-synthase in osteoblasts may explain the blunting of the bone anabolic response to PTH observed after chronic exposure of rats to bisphosphonates. Osteoporos Int 2006; 17: S68–69.
40. Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res 2009; 24: 1132–1134.
41. Singer FR. Bone quality in Pagets disease of bone. Curr Osteoporos Rep 2016; 14: 39–42.
42. Lo JC, Hui RL, Grimsrud CD et al. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 2016; 85: 142–147.
43. Lu Liquing, Lu Lifen, Zhang J, et al. Potential risks of rare serious adverse effects related to long-term use of bisphosphonates: An overview of systematic reviews. J Clin Pharm Ther 2020; 45: 45–51.
44. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115–1117.
45. Lee SH, Chang SS, Lee M, et al. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta–analysis. Osteoporos Int 2014; 25(3): 1131–1139.
46. Lee S, Yin RV, Hirpara H, et al. Increased risk for atypical fractures associated with bisphosphonate use. Fam Pract 2015; 32(3): 276–281.
47. Gedmintas L, Solomon DH, Kim SC, et al. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical ferur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013; 28(8): 1729–1737.
48. Lu YJ, Liu H. Meta-analysis of the relationship between bisphosphonates and atypical femoral fractures. Chin J Clinicians 2013; 7(20): 102–104.
49. Lin T, Wang C, Cai XZ, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 2012; 66(4): 399–408.
50. Chen LX, Ning GZ, Zhou ZR, et al. The carcinogenity of alendronate in patients with osteoporosis: evidence from cohort studies. PlosOne 2015; 10(4): e0123080.
51. Molvik H, Khan WS. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int 2015; 26(4): 1251–1260.
52. Yue B, Ng A, Tang H, et al. Delayed healing of lower limb fractures with bisphosphonate therapy. Ann R Coll Surg Engl 2015; 97(5): 333–338.
53. Cosman F. Long term treatment strategies for postmenopausal osteoporosis. Curr Opin Rheumatol 2018; 30: 420–426.
54. Pinkerton JAV, Aguirre FS, Blake J, et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017; 24: 728–753.
55. Lello S, Capozzi A, Scambia G. The tissue-selective estrogen complex (bazedoxifene/conjugated estrogens) for the treatment of menopause. Int J Endocrinol 2017; 2017: 5064725.
56. Cummings SR, Cosman F, Lewiecki EM, et al. Goal directed treatment for osteoporosis: a progress report from the ASBMR-NOR Working Group on goal-directed treatment for osteoporosis. J Bone Miner Res 2017; 32: 3–10.
57. Cosman F, Cauley JA, Eastell R, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab 2014; 99: 4546–4554.
58. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report for a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31: 1910.
59. McClung MR. Cancel the denosumab holiday. Osteoporos Int 2016; 27: 1677–1682.
60. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017; 5: 513–523.
61. Black DM, Reidl IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomised second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015; 30: 934–944.
62. Ferrari S, Adachi JD, Loppuner K, et al. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 2015; 26: 2763–2771.
63. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017; 105: 11–17.
64. McClung MR, Wagman RB, Miller PD, et al. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 2017; 28: 1723.
65. Cummings SR, Ferrari S, Eastel R, et al. Vertebral fractures after discontinuation of denosumab: a post hock analysis of the randomised placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 2018; 33: 190–198.
66. Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 2016; 27: 1929–1930.
67. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, et al. Several spontaneus vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 2016; 27: 1923–1925.
68. Lamy O, Gonzalez-Rodriguez E, Stoll D, et al. Severe rebound–associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 2016; 102: 354–358.
69. Polyzos SA, Terpos E. Clinical vertebral fractures following denosumab discontinuation. Endocrine 2016; 54: 271.
70. Popp A, Zysset P, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab: from clinic and biomechanice. Osteoporos Int 2016; 27: 1917–1921.
71. Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound–associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017; 32: 1291–1296.
72. Roux C, Briot K. Imminent fracture risk. Osteoporos Int 2017; 28: 1765–1769.
73. van Geel TA, Huntjens KM, van den Bergh JP, et al. Timing of subsequent fracture after an initial fracture. Curr Osteoporos Rep 2010; 8: 118–122.
74. Kanis J. Characteristics of recurrent fractures. Osteoporos Int 2018; 29(8): 1747–1757.
75. Balasubramanian A. Risk of subsequent fractures after prior fracture among older women. Osteoporos Int 2019; 30(1): 79–92.
76. Gehlbach S, Saag KG, Adachi JD, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res 2012; 27: 645–653.
77. Cosman F, Krege JH, Looker AC, et al. Spine fracture prevalence in a nationally representative sample og US women and men aged over 40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013–2014. Osteoporos Int 2017; 28: 1857–1866.
78. Lewiecki EM, Binkley N, Morgan SL, et al. Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom 2016; 19: 127–140.
79. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2016. Endocr Pract 2016; 22(Suppl 4): 1–42.
80. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756–765.
81. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–1822.
82. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomised extension to the HORIZON-Pivotal Fracture Triat (PFT). J Bone Miner Res 2012; 27: 243–244.
83. Cummings S, Vittinghoff E, Daizadeh N, et al. Virtual twin estimates: continued new vertebral and nonvertebral anti–fracture efficacy through 8 years of treatment with denosumab. Abstract. ASBMR; 2014; S114–S120.
84. Cosman F, Nieves JW, Dempster DW, et al. Treatment sequence matters: anabolic and antiresrptive therapy for osteo-porosis. J Bone Miner Res 2017; 32: 198–202.
85. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transition in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015; 386: 1147–1155.
86. Langdahl BL, Libanati C, Crittenden DB, et al. Romosotumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a Rndomised, open-label, phase 3 trial. Lancet 2017; 390: 1585–1594.
87. Brown JP. Antiresorptives: Safety concerns-clinical perspective. Toxicologic Pathology 2017; 45(7): 859–863.
88. Vang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 2011; 26: 553–560.
89. Brown JP, Morin S, Leslie W, et al. Bisphosphonates for treatment of osteoporosis: Expected benefits, potential harms, and drug holidays. Can Fam Physician 2014; 60: 324–333.
90. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update Executive Summary. Endocr Pract 2020; 26(5): 564–570.
91. Kanis JA, Cooper C, Rizzoli R, Reginster JY, et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 2019; 104: 235–238.